Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-24
2007-04-24
Landsman, Robert S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S458000, C514S470000, C514S474000, C514S706000
Reexamination Certificate
active
10164863
ABSTRACT:
SR-BI is present at relatively high levels on the membranes of hepatocytes and steroidogenic tissues, including the adrenal gland, testes, and ovaries, where it mediates the uptake and transport of cholesteryl ester from high density lipoproteins. It has been demonstrated that transgenic animals which do not produce SR-BI are healthy, with the exception that the females are infertile. SR-BI KO females have abnormal HDLs, ovulate dysfunctional oocytes and are infertile. Surgical, genetic and pharmacologic methods were used to show that the fertility of SR-BI KO females (or their transplanted oocytes) can be restored in the absence of ovarian and/or extraovarian SR-BI expression by manipulations that modify the structure, composition and/or abundance of their abnormal plasma lipoproteins. These manipulations included inactivation of the apolipoprotein A-I gene and administration of the cholesterol-lowering drug PROBUCOL™. In the absence of treatment, female animals which do not express SR-BI have dramatically reduced levels of offspring, even though they are otherwise healthy and the males normal. Studies demonstrate that they do not produce viable eggs and have a defect involving implantation of normal eggs.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), River et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslaghti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5674488 (1997-10-01), Reich
patent: 5962322 (1999-10-01), Kozarsky et al.
patent: 5965790 (1999-10-01), Acton
patent: 6121319 (2000-09-01), Somers
patent: 2002/0016364 (2002-02-01), Luchoomun et al.
patent: 2002/0099040 (2002-07-01), Krieger
patent: WO 93/01286 (1993-01-01), None
patent: WO 96/00288 (1996-01-01), None
patent: WO 97/18304 (1997-05-01), None
Bertolotti M et al. J. Lipid Research. 37:1812-1822, 1996.
Abumrad, et al., “Cloning of a Rat Adipocyte Membrane Protein Implicated in Binding or Transport of Long-chain Fatty Acids That Is Induced during Preadipocyte Differentiation,”J. Biol. Chem. 268:17665-17668 (1993).
Acton, et al., “Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor,”J. Biol. Chem. 269(33): 21003-21009 (1994).
Acton, et al., “The Collagenous Domains of Macrophage Scavenger Receptors and Complement Component C1q Mediate Their Similar, But Not Identical, Binding Specificities for Polyanionic Ligands,”J. Biol. Chem. 268: 3530-3537 (1993).
Acton, et al., “Identification of scavenger receptor SR-BI as a high density lipoprotein receptor,”Science271: 518-520 (1996).
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA, 85:7079-7083 (1988).
Arai, et al., “Multiple Receptors for Modified Low Density Lipoproteins in Mouse Peritoneal Macrophages: Different Uptake Mechanisms for Acetylated and Oxidized Low Density Lipoproteins,”Biochem. Biophys. Res. Commun159:1375-1382 (1989).
Asch, et al., “Isolation of the Thrombospondin Membrane Receptor,”J. Clin.—Invest. 79:1054-1061 (1987).
Askew, et al., “Molecular Recognition with Convergent Functional Groups, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”,J. Am. Chem. Soc. 111: 1082-1090 (1989).
Bajetta, et al., “Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer,”Br. J. Cancer70: 145-150 (1994).
Baldini, et al., “Cloning of a Rab3 Isotype Predominately Expressed in Adipocytes”,Proc. Natl. Acad. Sci. U.S.A. 89: 5049-5052 (1992).
Bickel, et al., “Rabbit Aortic Smooth Muscle Cells Express Inducible Macrophage Scavenger Receptor Messenger RNA that is Absent from Endothelial Cells”,J. Clin. Invest. 90: 1450-1457 (1992).
Blume, et al., “Triple Helix Formation by Purine-rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter”,Nucl. Acids Res. 20: 1777-1784 (1992).
Bork, et al., “Go hunting in sequence databases but watch out for the traps,”Trends in Genetics12: 425-427 (1996).
Bork, et al., “Powers and pitfalls in sequence analysis: the 70% hurdle,”Genome Research10: 398-400 (2000).
Brenner,“Errors in genome annotation,”Trends in Genetics15: 132-133 (1999).
Brown & Goldstein, “Lipoprotein Metabolism In The Macrophage: Implications for Cholesterol Deposition in Atherosclerosis”Annu. Rev. Biochem. 52: 223-261 (1983).
Calvo & Vega, “Identification, Primary Structure, and Distribution of CLA-1, a Novel Member of the CD36/LIMPII Gene Family”,J. Biol. Chem. 268: 18929:18935 (1993).
Charron, et al., “A Glucose Transport Protein Expressed Predominately in Insulin-responsive Tissues”,Proc. Natl. Acad. Sci. U.S.A. 86: 2535-2539 (1989).
Cirkel, et al., “Medical treatment of symptomatic endometriosis,”Human Reproduction11: 89-101 (1996).
Cooney, et al., “Site-Specfic Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro,”Science241: 456-459 (1988).
Crooke, “Progress Toward Oligonucleotide Therapeutics: Pharmacodynamic Properties”,FASEB J. 7: 533-539 (1993).
Doerks, et al., “Protein annotation: detective work for function prediction,”Trends in Genetics14: 248-250 ( 1998).
Doi, et al., “Charged Collagen Struture Mediates the Recognition of Negatively Charged Macromolecules by Macrophage Scavenger Receptors,”J. Biol. Chem. 268: 2126-2133 (1993).
Duval-Valentin, et al., “Specific Inhibition of Transcription by Triple Helix-Forming Oligonucleotides,”Proc. Natl. Acad. Sci. USA, 89: 504-508 (1992).
Endemann, et al. “CD36 Is a Receptor for Oxidized Low Density Lipoprotein”,J. Biol. Chem. 268: 11811-11816 (1993).
Fraser, et al., “Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor,”Nature364: 343-346 (1993).
Freeman, et al., “Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein”,Proc. Natl. Acad. Sci. U.S.A. 88: 4931-4935 (1991).
Glass, et al., “Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad,”Proc. Natl. Acad. Sci. USA80: 5435 (1983).
Goldstein, et al., “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition”,Proc. Natl. Acad. Sci. U.S.A. 76: 333-337 (1979).
Greenwalt, et al., “Membrane Glycoprotein CD36: A Review of Its Roles in Adherence, Signal Transduction, and Transfusion Medicine”,Blood80:1105-1115 (1992).
Gregoriadis, Chapter 14: “Liposomes”,Drug Carriers in Biology and MedicineAcademic Press, pp. 287-341 (1979).
Grigoriev, et al., “A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF KB Binding to Interleukin-2 Receptor α-Regulatory Sequence”,J. Biol. Chem. 267: 3389-3395 (1992).
Haberland, et al., “Two Distinct Receptors Account for Recognition of Maleyl-Albumin in Human Monocytes during Differentiation In Vitro”,J. Clin. Inves. 77: 681-689 (1986).
Herz, et al., “Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lip
Krieger Monty
Miettinen Helena E.
Landsman Robert S.
Pabst Patent Group LLP
LandOfFree
Lipid-altering compositions for the treatment of infertility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid-altering compositions for the treatment of infertility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid-altering compositions for the treatment of infertility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3725485